An overview of endometriosis and molecular target-based therapeutic approach

Deepraj Paul, Rohini Agrawal, Md Jalaluddin Iqbal
In: Middle East Fertility Society Journal · 2025 · vol. 30(1) · doi:10.1186/s43043-025-00219-8 · W4408674567
article OA: diamond CC0
📄 Open PDF View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

This review explores molecular targets and phytoconstituents like apigenin and curcumin as potential endometriosis therapies to decrease cell proliferation, invasion, and pain, and potentially increase fertility.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-06 ⓘ

This review discusses endometriosis as a chronic inflammatory estrogen-driven disorder with links to infertility and multiple comorbidities, summarizing its risk factors, complications, and pathological correlations (including frequent co-occurrence with adenomyosis) and describing current hormonal and surgical treatments and their limitations such as incomplete response, adverse effects, and recurrence. It proposes a molecular target–based therapeutic formulation composed of numerous phytoconstituents (e.g., apigenin, genistein, resveratrol, quercetin, curcumin, and others) and asserts that such a mixture could modulate many signaling and inflammatory pathways and reduce processes like ectopic stromal cell proliferation, invasion, vascularization, pain sensation, and inflammation; it also notes potential effects on gestational diabetes and fetal growth restriction. The paper explicitly cautions that further research is needed to determine safety, compatibility, and therapeutic efficacy of this proposed formulation. This paper is centrally about endometriosis — it provides an overview of endometriosis and a molecular target-based, phytochemical therapeutic approach, while also discussing relationships with adenomyosis and adenomyosis–endo comorbidity.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Abstract Background Endometriosis has become a global concern. Fifty percent of the affected women become infertile. Ten percent of the female population, which represents women in their reproductive age and girls, is affected globally. It shows a strong correlation with thyroid, endometrial, and breast cancer. It disrupts the psychological, social, and economic wellbeing and sexual life of women. Main body Modern hormonal therapy relies upon estrogen–progestin combinations. Other drugs include progestins, gonadotropin-releasing hormone agonists and antagonists. Some patients remain non-responsive to these therapies, and others show adverse effects such as intolerance, weight gain, acne, and seborrhea. Similarly, surgery has its own complications which include late bowel, ureteral perforations, recto-vaginal, and uretero-vaginal fistulas. Neither modern therapeutic nor surgical approaches could alleviate endometriosis. Besides, the cost of treatment is overburdening. This necessitates the designing of an alternative therapeutic approach which could alleviate endometriosis. This has led to the identification of molecular targets and the exploration of different phytoconstituents that could modulate these targets. Conclusion Formulation containing different phytoconstituents such as apigenin, genistein, resveratrol, 5α-hydroxycostic acid, hydroxyisocostic acid, anthocyanins, quercetin, naringenin, kaempferol, withaferin-A, ursolic acid, shogaol, curcumin, demethoxycurcumin, capsaicin, ellagic acid, 6‐paradol, 6‐gingerol, carnosic acid, tuberostemonine-O, rosmarinic acid, luteolin, granatin-B, and licochalcone-A may be useful in the treatment of emdometriosis. This formulation may decrease the proliferation of ectopic endometrial stromal cells, their invasion, vascularization, pain sensation, inflammation, gestational diabetes mellitus, and fetal growth restriction. There may be an increase in the fertility rate also. This is due to its ability to regulate the expression of many molecular targets such as VEGF-A/VEGFR2 pathway, p38MAPK/ERK-1/2/PI3K/protein kinase B (AKT), HIF-1α, IL-1β, IL-2, IL-6, IL-8, IL-10, IL-17A, IL-18, IL-33, TNF-α, NF-kB, IFN-γ, IGF-1-induced activation of IGF-1R, ER-α, and ER-β receptors, miR-95, miR-103, miRNA-138, miRNA-155, miR-183, miR-223, MMP-1, MMP-2, MMP-3, MMP-9, lncRNA-MEG3, lncRNA-H19, Ang-1 mRNA, Ang-2 mRNA, mRNA of urokinase plasminogen activator, mRNA expression and secretion of leptin, CD31, Tie-2, MCP-1 mRNA and protein, HGF, Nrf2, HO1, Keap1, COX-2, PGE-2, MKNK1, and human DNA TOP3A. However, further research is required to determine the safety, compatibility, and therapeutic efficacy of this formulation.

My notes (saved in your browser only)

Outcome instruments

rASRM Enzian

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK